Community Bank & Trust Waco Texas Acquires 2,164 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Community Bank & Trust Waco Texas grew its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 60.6% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 5,736 shares of the medical equipment provider’s stock after purchasing an additional 2,164 shares during the period. Community Bank & Trust Waco Texas’ holdings in Zimmer Biomet were worth $698,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of ZBH. Vontobel Holding Ltd. grew its stake in shares of Zimmer Biomet by 4.5% in the third quarter. Vontobel Holding Ltd. now owns 8,540 shares of the medical equipment provider’s stock valued at $958,000 after buying an additional 366 shares in the last quarter. IFP Advisors Inc raised its stake in Zimmer Biomet by 20.4% in the third quarter. IFP Advisors Inc now owns 2,763 shares of the medical equipment provider’s stock valued at $310,000 after purchasing an additional 469 shares in the last quarter. PFG Advisors grew its stake in Zimmer Biomet by 7.5% during the third quarter. PFG Advisors now owns 1,815 shares of the medical equipment provider’s stock worth $204,000 after buying an additional 126 shares in the last quarter. Ziegler Capital Management LLC increased its stake in Zimmer Biomet by 10.2% in the third quarter. Ziegler Capital Management LLC now owns 30,915 shares of the medical equipment provider’s stock valued at $3,469,000 after acquiring an additional 2,852 shares during the last quarter. Finally, Montecito Bank & Trust raised its position in Zimmer Biomet by 4.6% during the third quarter. Montecito Bank & Trust now owns 2,272 shares of the medical equipment provider’s stock valued at $255,000 after purchasing an additional 100 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of the stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the completion of the sale, the vice president now owns 44,145 shares of the company’s stock, valued at $5,677,929.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.70% of the stock is currently owned by insiders.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock traded up $0.37 during mid-day trading on Wednesday, hitting $121.89. 252,506 shares of the stock were exchanged, compared to its average volume of 1,448,724. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $149.25. The company has a market capitalization of $25.04 billion, a P/E ratio of 24.85, a P/E/G ratio of 2.22 and a beta of 1.01. The company has a 50-day simple moving average of $126.19 and a 200 day simple moving average of $119.44. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping the consensus estimate of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. During the same quarter in the prior year, the company earned $1.88 EPS. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date of this dividend is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio is currently 19.63%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ZBH shares. Citigroup lifted their price target on Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. JPMorgan Chase & Co. increased their price objective on shares of Zimmer Biomet from $115.00 to $125.00 and gave the company a “neutral” rating in a research note on Friday, February 9th. Barclays boosted their target price on shares of Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a research note on Monday, February 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 9th. Finally, Raymond James upped their price objective on Zimmer Biomet from $133.00 to $137.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $139.39.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.